Salarius Pharmaceuticals, Inc. (SLRX) Dividend History

Company News

• Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight

  The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development.

  GlobeNewswire Inc.

  Featured Companies: INCY PFE
• Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

  Salarius Pharmaceuticals reported a net loss of $5.6 million for 2024, down from $12.5 million in 2023. The company is progressing with a planned merger with Decoy Therapeutics, which is expected to accelerate the development of novel peptide conjugate therapeutics. Salarius also has an ongoing investigator-initiated Phase 1/2 clinical trial of seclidemstat in combination with azacitidine to treat hematologic cancers.

  GlobeNewswire Inc.
• Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket - Benzinga

  Tellurian Inc. shares rose sharply after Woodside Energy announced plans to acquire the company for $900 million. Several other stocks also saw significant pre-market movement, both positive and negative.

  Benzinga

  Featured Companies: CISO NCPL OFG ONCO PRTG RR SERV SGD VEEE
• Salarius Pharmaceuticals ends Ewing sarcoma trial - Investing.com

  Salarius Pharmaceuticals is discontinuing its Phase 1/2 clinical trial for the drug seclidemstat in the treatment of Ewing sarcoma. The company is seeking strategic alternatives to maximize shareholder value as it faces financial and operational challenges.

  Investing.com
• Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga

  Intuitive Surgical reported better-than-expected Q2 results, causing its shares to rise 6.7% in premarket trading. Several other stocks also saw significant premarket movements, both positive and negative.

  Benzinga

  Featured Companies: CRWD HE IMPP IMPPP ISRG KITT PLUG S SERV SMXT SPWR SXTP